康士得联合睾丸切除治疗晚期前列腺癌

Combined cascodex and castration therapy for advanced prostate cancer

目的 :观察康士得治疗晚期前列腺癌 (PCa)的疗效。方法 :应用康士得联合睾丸切除治疗晚期PCa和缓退瘤抵抗患者。结果 :① 10例原发PCa治疗 3个月 ,血清前列腺特异抗原 (PSA)降至 (4 .6 7± 2 .5 8) μg/L ,与治疗前比较差异有极显著性意义 (P <0 .0 1)。其中 8例完全降至正常 ,2例下降 >90 %。患者临床症状均改善 ,前列腺体积明显缩小 (P <0 .0 1)。治疗 12～ 18个月 ,无一例出现PSA反跳。② 2例缓退瘤抵抗患者 ,改服康士得后 ,PSA最大降幅分别为 76 %和 81% ,显示对继续阻断雄激素依然有效。结论 :康士得联合睾丸切除治疗晚期PCa有较好疗效。

Purpose:To investigate the effect of combined cascodex and castration therapy in patients with advanced prostate cancer. Methods:After surgical castration , cascodex(50 mg/d)were administered to 10 patients with primary advanced prostate cancer , 2 patients with flutamide withdrawal syndrome. Results:①Serum PSA levels in 10 (3 months later ) was ( 4.67 ± 2.58 ) μg/L, showed a significant decline than that of untreated before(P< 0.01 ). In 8 the PSA declined to baseline , and 2 more than 90%.Clinical symptoms improved in all patients and the prostate volume became smaller(P< 0.01 ). PSA levels stabilized during 24 months.②2 patients with flutamide withdrawal syndrome still had successful effect instead of treatment by cascodex .The maxim decline in PSA was 76%, 81%, respectively. Conclusions:Combined cascodex and cascodex therapy was effective for advanced prostate cancer .